Resumption or persistence of menstruation after cytotoxic chemotherapy is a prognostic factor for poor disease-free survival in premenopausal patients with early breast cancer

Annals of Oncology

Volumn 23, Issue 9, 2012, Pages 2283-2289

  Park, I H ^a   Han, H S ^b   Lee, H ^a   Lee, K S ^a   Kang, H S ^a   Lee, S ^a   Kim, S W ^a   Jung, S ^a   Ro, J ^a  

^a National Cancer Center   (South Korea)

^b Chungbuk Provincial College   (South Korea)

Author keywords

Adjuvant chemotherapy; Breast cancer; Chemotherapy induced amenorrhea; Premenopause

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; HORMONE RECEPTOR; METHOTREXATE; TAMOXIFEN;

ADULT; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREMENOPAUSE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME;

EID: 84865572297     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds006     Document Type: Article

References (19)

1. Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 2006; 24: 5769.
2. Levine MN, Bramwell VH, Pritchard KI et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998; 16: 2651.
3. Bonadonna G, Brusamolino E, Valagussa P et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294: 405-410.
4. Han HS, Ro J, Lee KS et al. Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Res Treat 2009; 115: 335-342.
5. Vanhuyse M, Fournier C, Bonneterre J. Chemotherapy-induced amenorrhea: influence on disease-free survival and overall survival in receptor-positive premenopausal early breast cancer patients. Ann Oncol 2005; 16: 1283.
6. Parulekar WR, Day AG, Ottaway JA et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study- NCIC CTG MA. 5. J Clin Oncol 2005; 23: 6002-6008.
7. Petrek JA, Naughton MJ, Case LD et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006; 24: 1045.
8. Pagani O, O'Neill A, Castiglione M et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 1998; 34: 632-640.
9. Colleoni M, Gelber S, Goldhirsch A, International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 2006; 24: 1332-1341.
10. Poikonen P, Saarto T, Elomaa I et al. Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patients. Eur J Cancer 2000; 36: 43-48.
11. Group IBCSTamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 2006; 24: 1332-1341.
12. Jung KW, Park S, Kong HJ et al. Cancer statistics in Korea: incidence, mortality and survival in 2006-2007. J Korean Med Sci 2010; 25: 1113.
13. Yu B, Douglas N, Ferin MJ et al. Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer 2010; 116: 2099-2105.
14. Kil WJ, Ahn SD, Shin SS et al. Treatment-induced menstrual changes in very young (< 35 years old) breast cancer patients. Breast Cancer Res Treat 2006; 96: 245-250.
15. Swain SM, Jeong JH, Geyer CE, Jr et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 2010; 362: 2053-2065.
16. Swain SM, Jeong JH, Wolmark N. Amenorrhea from breast cancer therapy-not a matter of dose. N Engl J Med 2010; 363: 2268-2270.
17. Karlsson P, Sun Z, Braun D et al. Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. Ann Oncol 2011; 22: 2216-2226.
18. Jonat W, Kaufmann M, Sauerbrei W et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002; 20: 4628.
19. Colleoni M, Cole BF, Viale G et al. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol 2010; 28: 2966.